TY - JOUR
TI - The efficacy and tolerability of tetracyclines and clindamycin plus
rifampicin for the treatment of hidradenitis suppurativa: Results of a
prospective European cohort study
AU - van Straalen, Kelsey R.
AU - Tzellos, Thrasyvoulos
AU - Guillem, Phillipe
AU - and Benhadou, Farida
AU - Cuenca-Barrales, Carlos
AU - Daxhelet, Mathilde
AU - and Daoud, Mathieu
AU - Efthymiou, Ourania
AU - Giamarellos-Bourboulis,
AU - Evangelos J.
AU - Jemec, Gregor B. E.
AU - Katoulis, Alexandros C. and
AU - Koenig, Anke
AU - Lazaridou, Elizabeth
AU - Marzano, V, Angelo and
AU - Matusiak, Lucas
AU - Molina-Leyva, Alejandro
AU - Moltrasio, Chiara and
AU - Pinter, Andreas
AU - Potenza, Concetta
AU - Romani, Jorge
AU - Saunte,
AU - Ditte M.
AU - Skroza, Nevena
AU - Stergianou, Dimitra
AU - Szepietowski,
AU - Jacek
AU - Trigoni, Anastasia
AU - Vilarrasa, Eva
AU - van der Zee, Hessel
AU - H.
JO - Journal of the American Academy of Dermatology
PY - 2021
VL - 85
TODO - 2
SP - 369-378
PB - MOSBY-ELSEVIER
SN - 0190-9622, 1097-6787
TODO - 10.1016/j.jaad.2020.12.089
TODO - acne inversa; antibiotics; clindamycin; doxycycline; efficacy;
guideline; minocycline; outcome; rifampicin; tetracycline; therapy;
treatment
TODO - Background: Tetracyclines and clindamycin plus rifampicin combination
therapy are both considered first-line therapy in current hidradenitis
suppurativa guidelines. However, evidence for their efficacy is drawn
from small studies, often without validated outcomes.
Objective: To assess the 12-week efficacy of oral tetracyclines and a
combination of clindamycin and rifampicin. Methods: A prospective,
international cohort study performed between October 2018 and August
2019.
Results: In total, 63.6% of the included 283 patients received oral
tetracyclines, and 36.4% were treated with clindamycin and rifampicin.
Both groups showed a significant decrease in International Hidradenitis
Suppurativa Severity Score System from baseline (both P < .001). The
Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in
40.1% and 48.2% of patients, respectively (P = .26). Patient
characteristics or disease severity were not associated with the
attainment of HiSCR or the minimal clinically important differences for
the Dermatology Life Quality Index and pain.
Limitations: Cohort study. Respectively, 23.9% and 19.4% of patients
had to be excluded from the HiSCR analysis for the tetracycline and
combination therapy group because of a low abscess and nodule count at
baseline.
Conclusion: This study shows significant efficacy of both tetracycline
treatment and clindamycin and rifampicin combination therapy after 12
weeks in patients with hidradenitis suppurativa. No significant
differences in efficacy were observed between the 2 treatments,
regardless of disease severity.
ER -